Patent application number | Description | Published |
20080311191 | Multi-Layer Tablets and Bioadhesive Dosage Forms - Bioadhesives coatings increase the gastrointestinal retention time of orally-ingested medicaments. Certain bioadhesive coatings producing a fracture strength of at least 100 N/m | 12-18-2008 |
20090018033 | Cell Aggregation and Encapsulation Device and Method - The invention is a cell aggregation device comprising a hydrogel substrate having at least one, preferably a plurality, of cell-repellant compartments recessed into the uppermost surface. Each compartment is composed of an upper cell suspension seeding chamber having an open uppermost portion and a bottom portion, and one, or more than one, lower cell aggregation recess connected to the bottom portion of the upper cell suspension seeding chamber by a port. The diameter of the port may be fully contiguous with the walls of the chambers and walls of the recesses, or the diameter of the port may be more narrow than the walls of the chamber but fully contiguous with the walls of the recesses or more narrow than both the walls of the chamber and the walls of the recesses. The upper cell suspension seeding chambers are formed and positioned to funnel the cells into the lower cell aggregation recesses through gravitational force. The aggregation recesses are formed and positioned to promote cellular aggregation by coalescing cells into a finite region of minimum gravitational energy, increasing intercellular contact and minimizing or preventing cell adherence to the substrate. A device for encapsulating aggregates of live cells is provided. The device comprises (i) a biocompatible, bio-sustainable substrate having a cell-encapsulating face composed of one or more biocompatible, bio-sustainable, spaced-apart, cell-encapsulating compartments extending therefrom and (ii) a coating layer composed of a biocompatible, bio-sustainable polymer that completely surrounds the substrate and the cell-encapsulating compartments. A method for making the device is also provided. | 01-15-2009 |
20090022777 | Methods for progenitor cell recruitment and isolation - The invention relates to the use of one or more growth factors in a drug delivery system, optionally with an external mesh housing, to recruit and optionally harvest progenitor cells. These cells include those that normally reside in the bone marrow. | 01-22-2009 |
20090217840 | CELLULAR OR ORGANELLE-ENTRAPPED NANOPARTICLES - The invention provides tissue marking pigment or dye particle retained within a tissue cell, the cellular cytoplasm, or one or more intracellular organelles. Also, the invention provides nanoparticles, which are phagocytosed, engulfed or otherwise entrapped by cells. | 09-03-2009 |
20090311295 | PARTICLES WITH HIGH UNIFORM LOADING OF NANOPARTICLES AND METHODS OF PREPARATION THEREOF - Methods to produce polymeric microparticles containing nanoparticles such, as pigments, dyes and other chromophores for cosmetic use, plastic surgery therapeutic use, and tattoos have been developed. The microparticles contain within the polymer a very uniform dispersion of dye particles. The methods by which the particles are made ensure a homogeneous mixture and high loading. The microparticles are made using air, one of a number of known methods such as phase inversion, solvent evaporation, and melt processing. The improvement is in the use of a method that makes, a stable dispersion of the nanoparticles in the liquid polymer before formation of the microparticles. This is achieved through selection of appropriate solvent, optionally including surfactant, and then subjecting the dispersion to mechanical processing that stabilizes the dispersion within the polymer solvent, so that the nanoparticles remain suspended for at least thirty minutes, in some cases two hours to 48 hours, sometimes up to three months. The mechanical processing can be sonication and/or production of shear forces, for examples, resulting from use of an open blade or rotor stator mixer or milling with a concentric shaft, at a speed such as between 5000 and 25,000 RPM. | 12-17-2009 |
20100172998 | PROCESS FOR PREPARING MICROPARTICLES THROUGH PHASE INVERSION PHENOMENA - A process for preparing nanoparticles and microparticles is provided. The process involves forming a mixture of a polymer and a solvent, wherein the solvent is present in a continuous phase and introducing the mixture into an effective amount of a nonsolvent to cause the spontaneous formation of microparticles. | 07-08-2010 |
20110166218 | METHODS FOR MICRONIZATION OF HYDROPHOBIC DRUGS - The invention involves methods and products related to the micronization of hydrophobic drugs. A method of micronizing hydrophobic drugs using a set of solutions including an aqueous solution is provided. The invention also relates to products of micronized hydrophobic drugs and related methods of use. | 07-07-2011 |
20120009267 | NANOPARTICLE COMPOSITIONS AND METHODS FOR IMPROVED ORAL DELIVERY OF ACTIVE AGENTS - Nanoparticles, compositions, and methods for the improved uptake of active agents are disclosed herein. The compositions contain a monodisperse population of nanoparticles, preferably including an active agent, where the nanoparticles are formed from a polymeric material possessing specified bioadhesion characteristics. Following enteral administration, preferably oral administration, the nanoparticles exhibit total intestinal uptakes of greater than 20%, preferably greater than 45%, more preferably greater than 65%. When compared to uptake of the same composition in the absence of the bioadhesive polymeric material, the nanoparticles have significantly increased uptake with intestinal uptake of the increased by more than 100%, preferably even greater than 500%. Further disclosed herein is a method of producing multi-walled nanoparticles, as well as methods of using thereof. Multi-walled particles prepared using the method disclosed herein are useful for controlling the release of active agents. | 01-12-2012 |
20120179031 | METHODS AND SYSTEMS FOR PROLONGED LOCALIZATION OF DRUG DELIVERY - An effective method for prolonging localization of therapeutics within the rat gastrointestinal tract of at least about 12 hours is provided. The method includes localization of therapeutic agents that are nanoparticulated or nanoencapsulated. Attractive forces between an orally administered magnetic dose and an external magnet were monitored and internal dose motion in real time using biplanar videofluoroscopy was visualized. Tissue elasticity was quantified as a measure of tissue health by combining data streams. The methods address safety, efficacy, and monitoring capacity of magnetically localized doses and show a platform for testing the benefits of localized drug delivery. | 07-12-2012 |
20130095188 | Method of Encapsulating a Material Using Solvent Removal Technique, and Microspheres/Nanospheres/Matrix Made Therefrom Having Sustained Release Properties - A method of encapsulating a material includes providing a polymer solution including a solvent, and an aqueous solution including a hydrophilic material, mixing the polymer and aqueous solutions, sonicating the mixed solution to obtain a water-in-oil (W/O) emulsion, mixing the water-in-oil emulsion with an oil solution, sonicating the mixed solution to obtain a water-in-oil-in-oil (W/O/O) emulsion, and stirring the water-in-oil-in-oil emulsion in a bath to form a precipitate of encapsulated material and separate the solvent. | 04-18-2013 |
20130137702 | ANTICOAGULANT REVERSAL AGENTS - Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds. | 05-30-2013 |
20130189366 | DRUG DELIVERY SYSTEMS AND METHODS OF USE - Disclosed herein are systems for delivery of one or more molecules (such as a drug, for example, a small molecule, polypeptide, and/or nucleic acid) to a subject, for example to a targeted location in the subject. In some embodiments, the delivery system includes an encapsulated inducing agent or repressing agent and a plurality of cells. In some examples, the inducing agent or repressing agent and the cells are each separately encapsulated. In other examples, the encapsulated inducing agent or repressing agent and the cells are co-encapsulated. The cells include one or more genes which are operably linked to an inducible promoter or a repressible promoter which is inducible or repressible by the encapsulated inducing agent or repressing agent, respectively. Methods of use of the delivery systems, for example to treat or inhibit a disease or disorder in a subject, are also disclosed. | 07-25-2013 |
20130280319 | Compositions, methods and kits for therapeutic treatment with wet spun microstructures - Methods, compositions, systems, devices and kits are provided for preparing and using a multi-layer polymeric microstructure composition for delivering a therapeutic agent to a subject. In various embodiments, the therapeutic agent includes at least one selected from the group of: a drug, a protein, a sugar, a carbohydrate, and a nucleotide sequence. In related embodiments, the composition is a fiber, a suture, a sphere, an implant, or a scaffold. | 10-24-2013 |
20140120162 | Bioadhesive Drug Delivery Compositions - Compositions containing one or more active agents, one or more bioadhesives elements, and one or more charge masking agents are described herein. In some embodiments, the one or more active agents are biomolecules or macromolecules, such as polysaccharides, proteins, peptides, or nucleic acids, which are charged at physiological pH. The one or more charge masking agents are selected based on the nature of the charge on the active agent. The compositions may also contain one or more controlled release materials, such as extended or sustained release materials or delayed release materials, in order to modify release of the active agent. | 05-01-2014 |
20140178479 | Concentrated Felbamate Formulations for Parenteral Administration - Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or neurological injury or trauma. | 06-26-2014 |
20140207105 | Methods for Effectively and Rapidly Desensitizing Allergic Patients - Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions are administered to yield therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration, by intradermal administration, using for example, microneedles or microparticles, oral administration, using for example, enteric coated capsules or tablets, or autologous transfusion. In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestines. | 07-24-2014 |
20140271931 | Anti-Acne Topical Films - Topical formulations containing one or more pharmaceutically acceptable bioadhesive film-forming agent, one or more anti-acne agent, and an aqueous solvent in the form of a solution or suspension are described herein. The formulation may further contain one or more excipients, including evaporation suppressants, humectants, or plasticizers. When the formulation is contacted with the skin of a patient, the solvent evaporates and forms a thin, transparent, and solid bioadhesive film. The bioadhesive film adheres to the skin surface for a prolonged period of time and the anti-acne agent is released into the skin over a prolonged period of time. Typically, the bioadhesive film adheres to the skin for at least 60 minutes following administration of the formulation, preferably for at least 8 hours following administration, more preferably up to 24 hours following administration. The prolonged retention of the anti-acne agent at the site increases the amount of uptake into the skin. | 09-18-2014 |